Israel signed on Friday a deal to purchase 5 million doses of U.S. drug manufacturer Novavax' coronavirus vaccine.
The vaccine is produced using protein-based technology, and the Health Ministry said it would provide Israel technological diversity and a broader coronavirus response.
The vaccine will be given in two doses and will be subject to regulatory approval in Israel. It is expected to serve as another alternative for Israelis who cannot or do not wish to be vaccinated with an mRNA vaccine.